Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $144.4 million.

  • Bicycle Therapeutics' Total Non-Current Liabilities fell 962.06% to $144.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.4 million, marking a year-over-year decrease of 962.06%. This contributed to the annual value of $162.7 million for FY2024, which is 2599.52% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Total Non-Current Liabilities of $144.4 million as of Q3 2025, which was down 962.06% from $162.1 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Total Non-Current Liabilities ranged from a high of $229.7 million in Q2 2023 and a low of $78.9 million during Q1 2021
  • Over the past 5 years, Bicycle Therapeutics' median Total Non-Current Liabilities value was $144.4 million (recorded in 2025), while the average stood at $152.7 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Total Non-Current Liabilities skyrocketed by 10649.48% in 2021 and then plummeted by 2683.55% in 2024.
  • Bicycle Therapeutics' Total Non-Current Liabilities (Quarter) stood at $130.3 million in 2021, then grew by 4.41% to $136.0 million in 2022, then surged by 61.65% to $219.8 million in 2023, then dropped by 26.0% to $162.7 million in 2024, then fell by 11.25% to $144.4 million in 2025.
  • Its last three reported values are $144.4 million in Q3 2025, $162.1 million for Q2 2025, and $142.4 million during Q1 2025.